VAPH Vaso Active Pharmaceuticals Inc. featured news, full reports, and detailed charts
Vaso Active Pharmaceuticals Inc. (VAPH/VAPH.PK) Wrap Up:
Vaso Active Pharmaceuticals, Inc. focuses on the commercialization, marketing, and sale of over-the-counter (OTC) pharmaceutical products that incorporate a proprietary PENtoCORE technology. It also owns the OTC worldwide license to use and practice vaso active lipid encapsulated technology, a patchless, lipid-based delivery system. The company?s products include Osteon, an OTC external analgesic, to provide temporary relief from the muscular skeletal pain associated with arthritis; A-R Extreme, an OTC external analgesic, to provide temporary relief from the muscle and joint pain associated with athletic activity; and Termin8, an OTC antifungal lotion to treat athlete's foot. It also develops acne treatment, analgesic utilizing ibuprofen, first aid treatments, hand and body lotions, psoriasis treatment, and toenail fungus treatment products. Vaso Active Pharmaceuticals distributes its products to chain drug and grocery stores. The company was founded in 2001 and is based in Danvers, Massachusetts. Vaso Active Pharmaceuticals, Inc. is a subsidiary of BioChemics, Inc.www.vasoactive.us
5 Employees
Founded in 2001
Vaso Active Pharmaceuticals Inc. (VAPH:OTC)
|
Market Cap
291.5K
|
Total Revenue
53.4K
|
|
|
EBITDA
1.5M
|
DILUTED EPS TTM
-0.20
|
|
|
P/E
--
|
P/S
9.7x
|
|
|
Return On Asset
-799.27
|
Return On Equity
28.14
|
|
| K = Thousands M = Millions B = Billions | ||
VAPH Top Compensated Officers
Mr. Joseph Frattaroli
Acting Chief Executive Officer, President, Ch...
Age: 47
Total Annual Compensation: $175.0K
Dr. Stephen G. Carter Ph.D.
Chief Scientific Officer, Vice President and ...
Age: 56
Total Annual Compensation: $140.0K
Executives, Board Directors
Compensation as of Fiscal Year 2007.
Key developments for Vaso Active Pharmaceuticals Inc. (VAPH)
Vaso Active Deleted From OTCBB
04/1/2009
Vaso Active Pharmaceuticals Inc.’s Class A common stock will be deleted from OTCBB on April 2, 2009 because it filed Form 15. The registration of the firm will be terminated under 34 Act. The firm will now be added to NBB.
Vaso Files Form 15
03/31/2009
Vaso Active Pharmaceuticals, Inc. announced that it has made the strategic decision to voluntarily suspend filing of its reports under the Securities Exchange Act of 1934. Although the Company has not been required to make filings under the Act since 2007, it has until now remained a voluntary filer. At the present time, management has determined that it is in the best interest of the Company and its shareholders to eliminate the costs associated with those filings. This decision was made by the Company as part of its strategy to prevent any unnecessary resource allocation in order to allow the Company to preserve and maximize its longevity in pursuing its case for alleged negligence committed by the Company’s former law firm, Robinson Cole. The case is currently pending in the Suffolk Superior Court in Boston Massachusetts.
Vaso Active Pharmaceuticals Inc. Creates a Line of OTC Topical Products That Will Help Improve the Lives of Millions of People
04/11/2008
Vaso Active Pharmaceuticals Inc. has created a line of OTC topical products that will help improve the lives of millions of people who use over the counter health care products every day. VasoActive's topical products utilize an advanced formulation technology called PENtoCORE(R). This unique delivery system results in safe and effective products with certain advantages such as less odor, less greasy feel and no residue. People can now have the safety of a topical product without the side effects of using a pill.
VAPH Competitors
| Company | Last | Change |
| Bristol Myers Squibb Co | $24.46 USD | +0.43 |
| Elan Corporation | €4.36 EUR | +0.039 |
| Pfizer Inc | $18.36 USD | +0.25 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | VAPH | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 9.7x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | NM | Not Meaningful |
|
VAPH |
||
|
VAPH transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent News About Vaso Active Pharmaceuticals Inc.
More news for VAPH
VASO ACTIVE PHARMACEUTICALS INC Financials
Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Fundamental company data provided by Capital IQ. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. Real-...Click here to read the whole Article (external link)
VASO ACTIVE PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Show all filings for VASO ACTIVE PHARMACEUTICALS INC | Request a Trial to NEW EDGAR Online Pro Form 8-K for VASO ACTIVE PHARMACEUTICALS INC 31-Mar-2009Other Events, Financial Statements and Exhibits Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "...Click here to read the whole Article (external link)
VASO ACTIVE PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Expired Yahoo - Document Has Expired/e/090331/vaph.pk8-k.html Options that might be of interest: Go to the Yahoo! home page. Go to the Yahoo! Finance home page. Go to the Yahoo! Loan Center. Go to the Yahoo! Insurance Center. Other resources: Message Boards - Stock Chat - Finance Clubs ...Click here to read the whole Article (external link)
VASO ACTIVE PHARMACEUTICALS INC Files SEC form 8-K, Other Events
Show all filings for VASO ACTIVE PHARMACEUTICALS INC | Request a Trial to NEW EDGAR Online Pro Form 8-K for VASO ACTIVE PHARMACEUTICALS INC 30-Jan-2009Other Events Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, ...Click here to read the whole Article (external link)
VASO ACTIVE PHARMACEUTICALS INC Financials
Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Fundamental company data provided by Capital IQ. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. Real-...Click here to read the whole Article (external link)
VASO ACTIVE PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FORWARD-LOOKING INFORMATION This Quarterly Report on Form 10-Q contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "1934 Act"), that are based on management's exercise of business judgment as well as assumptions made by, and information currently available to management. When used in this document, the words "may," "will," "anticipate," "believe," "estimate," "intend," and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect our current view of future events and are subject to certain risks and uncertainties as noted below. Should one or more of these risks and uncertainties materialize, or should underlying assumptions prove incorrect, our actual results could differ materially from those anticipated in these forward-looking statements. We undertake no obligation and do not intend to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of any unanticipated events after the date hereof or to reflect the occurrence of any unanticipated events. Although we believe that our expectations are based on reasonable assumptions, we can give no assurance that our expectations will materialize. Management's Discussion and Analysis should be read together with our condensed financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q and the Company's Annual Report on Form 10-KSB for the fiscal year ended December 31, 2007. This Quarterly Report on Form 10-Q, including the following discussion, may contain trend analysis and other forward-looking s...Click here to read the whole Article (external link)
Would you like to leave a comment about Vaso Active Pharmaceuticals Inc. VAPH/VAPH.PK
Find out what social network information about Vaso Active Pharmaceuticals Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Vaso Active Pharmaceuticals Inc. there is more great information available at Realpennies.com